Trousseau's syndrome in association with ovarian carcinoma

Cancer

Volumn 77, Issue 12, 1996, Pages 2544-2549

  Evans, T R Jeffry ^a   Mansi, Janine L ^a   Bevan, David H ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

pulmonary embolism; Trousseau's syndrome; venous thromboembolism

Indexed keywords

ADULT; ANTICOAGULATION; ARTICLE; BLOOD CLOTTING; CASE REPORT; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HEMOSTASIS; HUMAN; HYPERCOAGULABILITY; OVARY CARCINOMA; PRIORITY JOURNAL; SYNDROME; THROMBOEMBOLISM; TREATMENT PLANNING;

FEMALE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS; SYNDROME; THROMBOPHLEBITIS;

EID: 0030006747     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19960615)77:12<2544::AID-CNCR18>3.0.CO;2-S     Document Type: Article

References (35)

1. Trousseau A. Phlegmasia alba dolens. Clinique Medicale de l'Hôtel - Dieu de Paris. London: New Sydenham Society, 1865;3:94.
2. Sack GH Jr, Levin J, Bell W. Trousseau's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms. Clinical, pathologic and therapeutic features. Medicine (Baltimore) 1977;56:1-37.
3. Hoerr SO, Harper JR. On peripheral thrombophlebitis: its occurrence as a presenting symptom of malignant disease of pancreas, biliary tract, or duodenum. JAMA 1957; 164:2033-44.
4. Liebermann JS, Borrero J, Urdanetta E, Wright IS. Thrombophlebitis and cancer. JAMA 1961;177:542-5.
5. Soong BCF, Miller SO. Coagulation disorders in cancer III. Fibrinolysis and inhibitors. Cancer 1970;25:867-73.
6. Ambrus JL, Ambrus CM, Mink IB, Pickren JW. Causes of death in cancer patients. J Med 1975;6:61-4.
7. Sproule EE. Carcinoma and venous thrombosis. The frequency of association of carcinoma in the body or tail of the pancreas with multiple venous thrombosis. Am J Cancer 1938;34:566-85.
8. Ambrus JL, Ambrus CM, Pickern J, Soldes S, Bross I. Haematologic changes and thromboembolic complications in neoplastic disease and their relationship to metastasis. J Med 1975;6:433-58.
9. Womack WS, Castellano CJ. Migratory thrombophlebitis associated with ovarian carcinoma. Am J Obstet Gynecol 1952;63:467-9.
10. Henderson PH. Multiple migratory thrombophlebitis associated with ovarian cancer. Am J Obstet Gynecol 1955;70:452-3.
11. Hubay CA, Holden WD. Venous thrombosis, necrosis and neoplasia. Surg Gynecol Obstet 1954;98:309-17.
12. Woolling KR, Snick RM. Thrombophlebitis. A possible clue to cryptic malignant lesions. Proc Staff Mtg Mayo Clinic 1956;31:227-37.
13. Begin LR, Raptis S. Diffuse pulmonary carcinomatous embolization, a rare and fatal manifestation of ovarian cancer. Gynecol Oncol 1991;41:250-4.
14. Viselli AL, Feuer GA, Granai CO. Lower limb ischemic venous thrombosis in patients with advanced ovarian carcinoma. Gynecol Oncol 1993;49:262-5.
15. Planner RS, O'Sullivan EF, Campbell JJ, Ball DL. The hypercoagulable state and pulmonary embolism in patients with ovarian carcinoma. Aust N Z J Obstet Gynaecol 1978;18:209-12.
16. Svendsen E, Karwinski B. Prevalence of pulmonary embolism at necropsy in patients with cancer. J Clin Pathol 1989;42:805-9.
17. Sun NC, McAfee WM, Hum GJ, Weiner JM. Haemostatic abnormalities in malignancy, a prospective study in one hundred and eight patients. Part 1. Coagulation studies. Am J Clin Pathol 1979;71:10-6.
18. Hagedorn AB, Bowie EJW, Elueback LR, Owen CA. Coagulation abnormalities in patients with inoperable lung cancer. Mayo Clin Proc 1974;49:649-53.
19. Carlsson S. Fibrinogen degradation products in serum from patients with cancer. Acta Chir Scand 1973;139:449-502.
20. Levin J, Conley CL. Thrombocytosis associated with malignant disease. Arch Intern Med 1964;114:497-500.
21. Davis RB, Theologizes A, Kennedy BJ. Comparative studies of blood coagulation and platelet aggregation in patients with cancer and non-malignant diseases. Ann Intern Med 1969;71:67-80.
22. Millar SP, Sanchez-Avalos J, Stefanski T, Zuckerman L. Coagulation disorders in cancer. Cancer 1967;20:1452-65.
23. Rasche H, Dietrich M. Haemostatic abnormalities associated with malignant diseases. Eur J Cancer 1977;13:1053-64.
24. Astedt B, Svanberg L, Nilssom IM. FDP [letter]. Lancet 1972;2:1312.
25. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, et al. Carboplatin dosage, prospective evaluation of a simple formulate based on renal function. J Clin Oncol 1989;7:1748-56.
26. Buckenham TM, George CD, Taylor RS. The use of human tissue type recombinant plasminogen activator in paraneoplastic arterial thrombosis - a non-surgical option. Australas Radiol 1992;36:97-8.
27. Bauer KA, Rosenberg RD. The pathophysiology of the prethrombotic state in tumors: insights gained from studies using markers of haemostatic system activation. Blood 1987;70:343-50.
28. Holvoet P, de Boer A, Vestreken M. An enzyme listed immunosorbent assay (ELISA) for the measurement of plasmin-alpha-2 - antiplasmin complex in human plasma. Application to the detection off in vivo activation of the fibrinolytic system. Thromb Haemost 1986;56:124-7.
29. Rickles FR, Edwards RL. Activation of blood coagulation in cancer. Trousseau's syndrome resisted. Blood 1983;62:14-31.
30. Dvorak FW. Thrombosis and cancer. Systemic abnormalities of haemostasis in cancer patients. Hum Pathol 1987;18:275-84.
31. Nanninga PB, van Teunesbroek A, Veenhof CHN, Bruller HR, ten Cate JW. Low prevalence of coagulation and fibrinolytic activation in patients with primary untreated cancer. Thromb Haemost 1990;64:361-4.
32. Haemostatic abnormalities and malignant disease [editorial]. Lancet 1986;1:303-4.
33. Duffy MJ, O'Grady P. Plasminogen activator and cancer. Perspectives and comments on. Eur J Cancer Clin Oncol 1984;20:577-82.
34. Richles FR, Hancock WW, Edwards RL, Zacharski LR. Anti-metastatic agents. Role of cellular procoagulants in the pathogenesis of fibrin deposition in cancer and the use of anticoagulants and/or antiplatelet drugs in cancer treatment. Semin Thromb Hemost 1988;14:88-94.
35. Bertina RM, Koelemann BP, Koster T, Rosendaal FR, Dirven RJ, de Rande H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994;369:14-5.